AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)PRNewsWire • 04/27/22
Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidateMarket Watch • 04/27/22
Why 5 of Warren Buffett's Highest-Yielding Stocks May Be the Best 2022 Ideas Now24/7 Wall Street • 04/21/22
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/19/22
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)PRNewsWire • 04/18/22
LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCERPRNewsWire • 04/10/22